Barclays analyst Nicholas Campanella maintained a Buy rating on Exelon (EXC – Research Report) today and set a price target of $42.00. The company’s shares closed yesterday at $40.44.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

If you’re looking to refinance—or in some cases buy a new home—a 10-year mortgage might be a good option for you. Here are the current 10-year mortgage rates and how you can find the right ...

Australia 10 Year Government Bond 0.0000 4.3689% ...

This January, Stasher, an innovative brand committed to helping you live life with less plastic through its line of reusable solutions, is offering “Resolution Relief,” a special initiative ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. We’ve spent hours evaluating each of the programs below based around the extra features ...

2024--Exelon Corp. (Nasdaq: EXC) announced today that it is consolidating the executive leadership team, with Gayle Littleton stepping down as Executive Vice President, Chief Legal Officer and ...

Illinois legalized online sports betting in 2020 and dozens of online sportsbooks are now operating in the state. In this guide, we’ll cover everything you need to know about online sports ...

Symptoms started 10 hours after application of the TTS and resolved after 15 days of treatment with a topical corticosteroid. Patch testing was performed with Transtec "as is" and with the ...

Transdermal therapeutic systems (TTSs) are commonly used to treat many diverse medical conditions. There are several advantages to this form of drug delivery; however, adverse cutaneous reactions ...